Verve Therapeutics
About Us
Why Heart Disease
Approach
Pipeline
Culture & Careers
News
Why Verve chose base editing over standard CRISPR for its lead CV candidate
Post navigation
Previous Post
Previous
With durable monkey data, Verve selects its first CRISPR base editing treatment for human trials
Next Post
Next
Beam, Verve stockpile cash as investors bank on gene editing progress
Home
About Us
Why Heart Disease
Approach
Pipeline
Culture & Careers
News
Contact Us